Table 2 MFI of cytokines produced by Th1, Th17 and Th1/Th17-lymphocytes in patients with AH, DM2, IGT and healthy volunteers, Me (Q1 – Q3)
Parameter | Healthy volunteers | Hypertensive patients | Hypertensive diabetic patients | Hypertensive patients with IGT |
|---|---|---|---|---|
(n = 12) | (n = 7) | (n = 20) | (n = 7) | |
MFI (IL-17) in Th17- lymphocytes (media) | 87 (49–108) | 81 (67–91) | 94 (74–97) | 74 (39–94) |
MFI (IFN-γ) in Th1- lymphocytes (media) | 27 (20–47) | 52 (36–77) | 50 (46–52)* | 46 (37–53) |
MFI (IL-17) in Th1/Th17- lymphocytes (media) | 479 (368–511) | 277 (255–336) | 351 (280–434) | 93 (63–237)*, **, # |
MFI (IFN-γ) in Th1/Th17- lymphocytes (media) | 375 (243–480) | 349 (305–349)* | 303 (166–381)* | 143 (81–309)* |
MFI (IL-17) in Th17- lymphocytes (PMA + ionomycin) | 131 (117–163) | 103 (98–109)* | 109 (87–129)* | 97 (83–114) |
MFI (IFN-γ) in Th1- lymphocytes (PMA + ionomycin) | 215 (63–400) | 132 (129–184) | 267 (187–318)** | 115 (76–181) |
MFI (IL-17) in Th1/Th17- lymphocytes (PMA + ionomycin) | 277 (200–386) | 163 (158–166) | 93 (64–168)* | 128 (48–175) |
MFI (IFN-γ) in Th1/Th17- lymphocytes (PMA + ionomycin) | 182 (118–197) | 209 (205–218) | 262 (220–505) | 102 (76–198)# |